Abstract
Objective: The aim of this study was to investigate the usefulness of Alzheimer’s disease Cerebrospinal Fluid (CSF) biomarkers in predicting the progression to dementia in patients with Mild Cognitive Impairment (MCI).
Methods: One hundred and thirteen patients were consecutively recruited from April 2012 to April 2014. Measurement of CSF biomarkers (amyloid-β42 (Aβ42), total tau (t-tau) and phosphorylated tau (p-tau)) and a neuropsychological evaluation were performed for all patients. We categorized patients with MCI as A+A- and N+N- based on the presence/absence of amyloid pathology and neurodegeneration, respectively. Results: Of 72 patients with MCI, 26 (36%) progressed to dementia. These patients had lower CSF Aβ42 levels and higher p-tau and t-tau levels at baseline. The proportion that progressed to dementia was 14.3% (2/14), 36.8% (7/19), 66.7% (4/6) and 75% (12/16) in the A-N-, A+N-, A-N+ (SNAP), and A+N+ patients, respectively (p < 0.05). There were significant differences in the probability of progression from amnestic MCI (aMCI) to AD between the A+N+ and A-N- patients (OR = 8.1, 95% CI 1.5-42.3, p = 0.001) but not between SNAP (OR = 7.3, 95% CI 0.9-61, p = 0.02) or A+N- (OR = 2.1, 95% CI 0.4 to 10.4, p = 0.15) patients compared to the A-N- subgroup. None of the biomarker profiles of the subgroups predicted the time until the progression to AD. Conclusion: The use of CSF AD biomarkers in clinical practice improves the certainty of diagnosis and prognosis of patients, especially in patients in the prodromal phase or in patients with atypical presentations.Keywords: Alzheimer's disease, mild cognitive impairment, biomarkers, amyloid, cerebrospinal fluid, prodromal phase.
Graphical Abstract
[1]
Bain LJ, Jedrziewski K, Morrison-Bogorad M, Albert M, Cotman C, Hendrie H, et al. Healthy brain aging: A meeting report from the Sylvan M. Cohen Annual Retreat of the Pennsylvania Institute on Aging. Alzheimers Dement 2008; 4: 443-6.
[2]
McKhann G, Drachman D, Folstein M, Robert K, Donald P, Emanuel MS. Clinical diagnosis of Alzheimer’s disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 1984; 34: 939-44.
[3]
Beach TG, Monsell SE, Phillips LE, Kukull W. Accuracy of the clinical diagnosis of Alzheimer disease at National Institute on Aging Alzheimer Disease Centers, 2005-2010. J Neuropathol Exp Neurol 2012; 71: 266-73.
[4]
Josephs KA, Whitwell JL, Ahmed Z, Shiung MM, Weigand SD, Knopman DS, et al. Beta-amyloid burden is not associated with rates of brain atrophy. Ann Neurol 2008; 63: 204-12.
[5]
Tapiola T, Alafuzoff I, Herukka SK, Parkkinen L, Hartikainen P, Soininen H, et al. Cerebrospinal fluid beta amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. Arch Neurol 2009; 66: 382-9.
[6]
Shaw LM, Vanderstichele H, Knapik-Czajka M, Christopher MC, Paul SA, Ronald CP, et al. Cerebrospinal fluid biomarker signature in Alzheimer’s disease neuroimaging initiative subjects. Ann Neurol 2009; 65: 403-13.
[7]
Mattsson N, Zetterberg H, Hansson O. CSF biomarkers and incipient Alzheimer disease in 501 patients with mild cognitive impairment. JAMA 2009; 302: 385-93.
[8]
Buchhave P, Minthon L, Zetterberg H. Cerebrospinal fluid levels of beta amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia. Arch Gen Psychiatry 2012; 69: 98-106.
[9]
McKhann GM, Knopman DS, Chertkow H. The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 2011; 7: 263-9.
[10]
Albert MS, DeKosky ST, Dickson D, Bruno D, Howard HF, Nick CF, et al. The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 2011; 7: 270-9.
[11]
Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, et al. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer’s disease. N Engl J Med 2014; 370: 322-33.
[12]
Doody RS, Thomas RG, Farlow M, Iwatsubo T, Vellas B, Joffe S, et al. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer’s disease. N Engl J Med 2014; 370: 311-21.
[14]
Trenerry M, Crosson B, de Boer J, Leber W. Stroop Neuropsychological Test Manual. Odessa, FL: Psychological Assessment Resoureces 1998.
[15]
Casals-Coll M, Sánchez-Benavides G, Quintana M, Manero RM, Rognoni T, Calvo L, et al. Spanish normative studies in young adults (NEURONORMA young adults project): Norms for verbal fluency tests. Neurologia 2013; 28(1): 33-40.
[16]
Peña-Casanova J, Quiñones-Úbeda S, Quintana-Aparicio M, Aguilar M, Badenes D, Molinuevo J. Spanish multicenter normative Studies (NEURORMA Project): norms for verbal Span, visuospatial span, letter and Lumber sequencing, trail making test, and symbol digit modalities test. Arch Clin Neuropsychol 2009; 24(4): 321-41.
[17]
Stallings G, Boake C, Sherer M. Comparison of the California verbal learning test and the rey auditory-verbal learning test in head-injured patients. J Clin Exp Neuropsychol 1995; 17: 706-12.
[18]
Peña-casanova J, Gramunt-Fombuena N, Quiñones-Úbeda S, Sánchez-Benavides G, Aguilar M, Badenes D. Spanish multicenter normatives Studies (NEURONORMA Project): Norms for the rey-osterrieth complex figure (copy and memory), and free and cued selective reminding test. Arch Clin Neuropsychol 2009; 24(4): 371-93.
[20]
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th edn, revised. Arlington, VA, USA: American Psychiatric Association 2000.
[21]
Caroli A, Prestia A, Galluzzi S, Ferrari C, van der Flier WM, Ossenkoppele R, et al. Mild cognitive impairment with suspected nonamyloid pathology (SNAP): Prediction of progression. Neurology 2015; 84: 508-15.
[22]
McKhann GM, Knopman DS, Chertkow H, Bradley TH, Clifford RJ, Claudia HK, et al. The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011; 7: 263-9.
[23]
Rascovsky K, Hodges JR, Knopman D, Mendez MF, Kramer JH, Neuhaus J, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain 2011; 134: 2456-77.
[24]
McKeith IG. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): Report of the consortium on DLB international workshop. Neurology 1996; 47: 1113.
[25]
Gorno-Tempini ML, Hillis AE, Weintraub S, Kertesz A, Mendez M, Cappa SF, et al. Classification of primary progressive aphasia and its variants. Neurology 2011; 76: 1006-14.
[26]
Blennow K, Hampel H. CSF markers for incipient Alzheimer’s disease. Lancet Neurol 2003; 2: 605-13.
[27]
Hampel H, Teipel SJ, Fuchsberger T, Andreasen N, Wiltfang J, Otto M, et al. Value of CSF betaamyloid1-42 and tau as predictors of Alzheimer’s disease in patients with mild cognitive impairment. Mol Psychiatry 2004; 9: 705-10.
[28]
Maruyama M, Matsui T, Tanji H, Nemoto M, Tomita N, Ootsuki M, et al. Cerebrospinal fluid tau protein and periventricular white matter lesions in patients with mild cognitive impairment: Implications for 2 major pathways. Arch Neurol 2004; 61: 716-20.
[29]
Lista S, Garaci FG, Ewers M, Steafn T, Henrik Z, Kaj B, et al. CSF Abeta1-42 combined with neuroimaging biomarkers in the early detection, diagnosis and prediction of Alzheimer’s disease. Alzheimers Dement 2014; 10: 381-92.
[30]
Vos S, Van Rossum I, Burns L, Dirk K, Philip S, Hilkka S, et al. Test sequence of CSF and MRI biomarkers for prediction of AD in subjects with MCI. Neurobiol Aging 2012; 22: 2272-81.
[31]
Lowe VJ, Peller PJ, Weigand SD, Catalina MQ, Nirubol T, Prashanthi V, et al. Application of the national institute on aging-alzheimer’s association AD criteria to ADNI. Neurology 2013; 80: 2130-7.
[32]
Galluzzi S, Geroldi C, Ghidoni R, Paghera B, Amicucci G, Bonetti M, et al. The new Alzheimer’s criteria in a naturalistic series of patients with mild cognitive impairment. J Neurol 2010; 257: 2004-14.
[33]
Eckerström C, Andreasson U, Olsson E, Rolstad S, Blennow K, Zetterberg H, et al. Combination of hippocampal volume and cerebrospinal fluid biomarkers improves predictive value in mild cognitive impairment. Dement Geriatr Cogn Disord 2010; 29: 294-300.
[34]
Jack CR Jr, Knopman DS, Jagust WJ, Leslie MS, Paul SA, Michael WW, et al. Hypothetical model of dynamic biomarkers of the Alzheimer’s pathological cascade. Lancet Neurol 2010; 9: 119-28.
[35]
Prestia A1, Caroli A, van der Flier WM. van der Flier, Rik O, Bart Van B, et al.. Prediction of dementia in MCI patients based on core diagnostic markers for Alzheimer disease. Neurology 2013; 80(11): 1048-56.
[36]
Jack CR Jr, Knopman DS, Weigand SD, Heather JW, Prashanthi V, Val L, et al. An operational approach to National Institute on Aging-Alzheimer’s Association criteria for preclinical Alzheimer disease. Ann Neurol 2012; 71: 765-75.
[37]
Nelson PT, Schmitt FA, Lin Y, Erin LA, Gregory AJ, Ela P, et al. Hippocampal sclerosis in advanced age: Clinical and pathological features. Brain 2011; 134: 1506-18.
[38]
Whitwell JL, Jack CR Jr, Przybelski SA, Joseph EP, Matthew LS, Bradley FB, et al. Temporoparietal atrophy: A marker of AD pathology independent of clinical diagnosis. Neurobiol Aging 2011; 32: 1531-41.
[39]
Chui HC, Zarow C, Mack WJ, William GE, Ling Z, William JJ, et al. Cognitive impact of subcortical vascular and Alzheimer’s disease pathology. Ann Neurol 2006; 60: 677-87.
Related Books
Frontiers in Clinical Drug Research - CNS and Neurological Disorders
Frontiers in Clinical Drug Research - CNS and Neurological Disorders
Frontiers in Clinical Drug Research - CNS and Neurological Disorders
Frontiers in Clinical Drug Research-Dementia
Frontiers in Clinical Drug Research - CNS and Neurological Disorders
Article Metrics
33
6
2
1